Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

gunagratinib (ICP-192)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

InnoCare

Drug class:

pan-FGFR inhib

Related drugs:

‹

erdafitinib (70)

erdafitinib (70)

›

FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	ICP-192 Sensitive: C2 – Inclusion Criteria ICP-192 Sensitive : C2	ICP-192 Sensitive: C2 – Inclusion Criteria ICP-192 Sensitive : C2
FGFR2 translocation	Cholangiocarcinoma	FGFR2 translocation	Cholangiocarcinoma	ICP-192 Sensitive: C3 – Early Trials ICP-192 Sensitive : C3	ICP-192 Sensitive: C3 – Early Trials ICP-192 Sensitive : C3
FGFR mutation	Solid Tumor	FGFR mutation	Solid Tumor	ICP-192 Sensitive: C3 – Early Trials ICP-192 Sensitive : C3	ICP-192 Sensitive: C3 – Early Trials ICP-192 Sensitive : C3
FGF mutation	Solid Tumor	FGF mutation	Solid Tumor	ICP-192 Sensitive: C3 – Early Trials ICP-192 Sensitive : C3	ICP-192 Sensitive: C3 – Early Trials ICP-192 Sensitive : C3
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	ICP-192 Sensitive: C3 – Early Trials ICP-192 Sensitive : C3	ICP-192 Sensitive: C3 – Early Trials ICP-192 Sensitive : C3